Non-aqueous high concentration reduced viscosity suspension formulations of antibodies

1. A non-aqueous high concentration suspension formulation, consisting of:

a. a vehicle, consisting of sesame oil as a hydrophobic agent and ethyl oleate as a viscosity-reducing agent; and

b. an antibody formulated with an excipient.

2. The formulation of claim 1 , wherein the antibody is an anti-TNFα antibody.

3. The formulation of claim 1 , wherein the amount of the viscosity-reducing agent in the vehicle is between 0.2%-95% by volume (% v/v) of the vehicle.

4. The formulation of claim 2 , wherein the anti-TNFα antibody is present at about 0.5%, 1%, 5%, 10%, 20%, 30%, 40%, 50% or 60% by weight (% w/w) of the formulation.

5. The formulation of claim 2 , wherein the anti-TNFα antibody is spray dried or lyophilized.

6. The formulation of claim 2 , wherein the anti-TNFα antibody comprises a light chain variable region (VL) of SEQ ID NO: 6 and a heavy chain variable region (VH) of SEQ ID NOs: 1 or 2, or a VL of SEQ ID NO: 7 and a VH of SEQ ID NOs: 3, 4, or 5.

7. The formulation of claim 6 , wherein the anti-TNFα antibody is of IgG1/k type.

8. The formulation of claim 1 , wherein the injection force of the formulation is equal to or less than 45 Newton (N), wherein the injection force is measured using a 1 mL rigid needle shield glass syringe having a 0.25 inch inside diameter, equipped with a 0.5 inch 26½ gauge needle at a 250 mm/min injection speed.

9. The formulation of claim 2 which is stable at 40° C. for at least one month.

10. The formulation of claim 2 , wherein the excipient is a carbohydrate, an amino acid, a buffer, or a non-ionic surfactant.

11. The formulation of claim 10 , wherein the carbohydrate is sucrose, trehalose, mannitol or sorbitol, the amino acid is histidine, isoleucine, methionine, glycine, arginine or lysine, the buffer is a histidine buffer or a citrate buffer, and the non-ionic surfactant is PS-80.

12. The formulation of claim 10 , wherein the weight ratio (w/w) of the carbohydrate to the anti-TNFα antibody is between about 0-3 or about 1-2, the weight ratio of the amino acid to the anti-TNFα antibody is between about 0-2 or about 0.3-1.8, the histidine buffer concentration is about 0-40 mM or about 5-10 mM, the citrate buffer concentration is about 0-10 mM or about 5-10 mM, and the non-ionic detergent is present at about 0%-0.5% (% w/v) or about 0.01-0.1% (% w/v).

13. A suspension formulation consisting of a particle formulation of anti-TNFα antibody having a light chain variable region (VL) of SEQ ID NO: 6 and a heavy chain variable region (VH) of SEQ ID NOs: 1 or 2, or a VL of SEQ ID NO: 7 and a VH of SEQ ID NOs: 3, 4, or 5, consisting of

a. 32.5 mg/mL of the anti-TNFα antibody, 10 mM histidine, 27.5 mg/mL sucrose, 0.01% (% w/v) PS-80;

b. 16.25 mg/mL of the anti-TNFα antibody, 10 mM histidine, 27.5 mg/mL sucrose, 0.01% (% w/v) PS-80;

c. 32.5 mg/mL of the anti-TNFα antibody, 10 mM citrate, 27.5 mg/mL sucrose, 0.01% (% w/v) PS-80;

d. 32.5 mg/ml of the anti-TNFα antibody, 10 mM histidine, 55 mg/ml sucrose, 10 mg/ml isoleucine, 0.01% (% w/v) PS-80;

e. 32.5 mg/ml of the anti-TNFα antibody, 10 mM histidine, 65 mg/ml sucrose, 0.01% (% w/v) PS-80;

f. 32.5 mg/ml of the anti-TNFα antibody, 5 mM histidine, 5 mM citrate, 65 mg/ml sucrose, 0.01% (% w/v) PS-80;

g. 32.5 mg/ml of the anti-TNFα antibody, 10 mM histidine, 5 mg/ml sucrose, 22.5 mg/mL mannitol, 0.01% (% w/v) PS-80;

h. 32.5 mg/ml of the anti-TNFα antibody, 10 mM histidine, 55 mg/ml trehalose, 10 mg/ml isoleucine, 0.01% (% w/v) PS-80; or

i. 65 mg/ml of the anti-TNFα antibody, 10 mM histidine, 55 mg/ml sucrose, 0.01% PS-80,

wherein the formulations shown in a-i are dispersed in a non-aqueous vehicle consisting of sesame oil and ethyl oleate, wherein the amount of ethyl oleate in the vehicle is between 0.2%-95% by volume (% v/v) of the non-aqueous vehicle.

14. The suspension formulation of claim 13 , wherein the amount of ethyl oleate in the vehicle is 5%, 10%, 15%, 30% or 50% (% v/v) of the non-aqueous vehicle.

15. The suspension formulation of claim 13 , wherein the anti-TNFα antibody is of IgG1/k type.